Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
RevMab
anti-Galectin-9 (human), Rabbit Monoclonal (RM499)
Product Details | |
---|---|
Synonyms | Gal-9; Ecalectin; Tumor Antigen HOM-HD-21; TIM-3 Ligand; T Cell Immunoglobulin and Mucin Domain-containing Protein 3 Ligand |
Product Type | Recombinant Antibody |
Properties | |
Clone | RM499 |
Isotype | Rabbit IgG |
Source/Host | Rabbit |
Immunogen/Antigen | A peptide corresponding to the N-terminus of human Galectin-9 (Gal-9). |
Application |
Immunohistochemistry (IHC): 1:100-1:200 dilution |
Crossreactivity | Human |
Specificity |
This antibody reacts to human Galectin-9. |
Purity | Protein A purified. |
Purity Detail | Protein A affinity purified from an animal origin-free culture supernatant. |
Concentration | N/A |
Formulation | Liquid. 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide. |
Isotype Negative Control | |
Other Product Data |
Click here for Original Manufacturer Product Datasheet |
Accession Number | O00182 |
Declaration | Manufactured by RevMab Biosciences. |
Shipping and Handling | |
Shipping | BLUE ICE |
Long Term Storage | -20°C |
Handling Advice | Avoid freeze/thaw cycles. |
Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. |
Documents | |
MSDS | Inquire |
Product Specification Sheet | |
Datasheet | Download PDF |
Galectin-9 (Gal-9), a β-galactoside-binding protein, primarily plays an immunosuppressive role in the tumor microenvironment, via binding with several cell surface receptors expressed on immune cells. Although Gal-9 was initially identified as a ligand for T-cell immunoglobulin and mucin domain–containing molecule 3 (TIM-3) in the induction of T-cell death, it also binds to other immunoregulatory receptors. For instance, Gal-9 binding to the innate receptor dectin-1 promotes M2 polarization of macrophages that suppresses antitumor immune responses. Gal-9 has also been shown to promote the differentiation of regulatory T cells (Tregs) through interaction with cluster of differentiation 44 (CD44) and drive the expansion of Tregs through binding with death receptor 3. The aberrantly high expression of Gal-9 in a range of cancers suggests that Gal-9 could be significant both as a biomarker and a therapeutic target.